A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
11/2006
11/16/2006	WO2006050838A3 Ophthalmic oil-in-water type emulsion with stable positive zeta potential
11/16/2006	WO2006050837A3 Ophthalmic emulsions containing an immunosuppressive agent
11/16/2006	WO2006050368B1 Therapeutic calcium phosphate particles iin use for aesthetic or cosmetic medicine, and methods of manufacture and use
11/16/2006	WO2006047695A3 Dosage forms having a microreliefed surface and methods and apparatus for their production
11/16/2006	WO2006002840A3 Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant
11/16/2006	WO2006002077A3 Stable pharmaceutical formulations of benzimidazole compounds
11/16/2006	WO2005084126A3 Method and device for releasing flavor and odor substances
11/16/2006	WO2005081968A3 Implant having mems flow module with movable, flow-controlling baffle
11/16/2006	WO2005079752A8 Controlled release pharmaceutical compositions with improved bioavailability
11/16/2006	WO2005072703A3 Controlled and sustained delivery of nucleic acid-based therapeutic agents
11/16/2006	WO2005067976A3 Direct compression formulation and process
11/16/2006	WO2005053648A8 Pre-metered dry powder inhaler for moisture-sensitive medicaments
11/16/2006	WO2005048977A3 Therapeutic foam comprising a sclerosing solution
11/16/2006	WO2004091614A8 Stabilized amlodipine maleate formations
11/16/2006	WO2004089287A3 Spray dry coacervation systems and methods
11/16/2006	WO2002094236A9 Delivery of antipsychotics through an inhalation route
11/16/2006	US20060259016 Reduced size implantable pump
11/16/2006	US20060259015 Implantable pump with infinitely variable resistor
11/16/2006	US20060258839 Cardiovascular disorders; antiinflammatory agents; resemble a G amphipathic helix of apolipoprotein J; phospholipids
11/16/2006	US20060258835 Implantable or ingestable medical device made of a polyesterether copolymer derived from an aromatic diacid, an aliphatic diacid, a polyalkylene glycol and a diol, for example, terephthalic acid, succinic acid, polyethylene glycol and butanediol; tissue engineering, sutures for example
11/16/2006	US20060258798 Methods for the dispersion of water-soluble of hydrophilic substances in a supercritically pressurized fluid
11/16/2006	US20060258745 Deramciclane-fumarate tablets
11/16/2006	US20060258735 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
11/16/2006	US20060258729 Antibacterial pyrazole carboxylic acid hydrazides
11/16/2006	US20060258703 Remedy for pruritus comprising piperidine derivative as the active ingredient
11/16/2006	US20060258617 Drug delivery to the back of the eye
11/16/2006	US20060258587 Modified MscL protein channel
11/16/2006	US20060258575 Sustained-release microparticle preparation of human growth hormone and process for producing thereof
11/16/2006	US20060258567 Xcrf polynucleotides and polypeptides and uses thereof
11/16/2006	US20060257495 Method of purification of polyalkylene materials
11/16/2006	US20060257494 Coated tablets
11/16/2006	US20060257493 Nanoparticulate delivery systems for treating multi-drug resistance
11/16/2006	US20060257492 Suspension of calcium phosphate particulates for local delivery of therapeutic agents
11/16/2006	US20060257491 Dry powder composition comprising co-jet milled particles for pulmonary inhalation
11/16/2006	US20060257490 Formulation based on phospholipids
11/16/2006	US20060257489 Fine particles, method and device for preparation thereof, and agent for parenteral injection and method for production thereof
11/16/2006	US20060257488 Injectable hydrogels and methods of making and using same
11/16/2006	US20060257487 Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
11/16/2006	US20060257486 Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
11/16/2006	US20060257485 composite materials with advanced properties such as for optics, electronic, magnetic, catalytic, semiconductive uses; in-situ synthesis of the inorganic oparticles on the surface of the polymer microspheres; control over the size of the nanoparticles
11/16/2006	US20060257484 Combination of tramadol and substances that comprise gabapentin
11/16/2006	US20060257483 Controlled release bupropion dosage forms
11/16/2006	US20060257482 Modified release, multiple unit drug delivery systems
11/16/2006	US20060257481 Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
11/16/2006	US20060257480 Pharmaceutical formulations of amyloid inhibiting compounds
11/16/2006	US20060257479 Long-acting molecules in sustained release formulations
11/16/2006	US20060257478 Acid-gas absorbing tablet and method of use
11/16/2006	US20060257477 Acid-gas absorbing tablet and method of use
11/16/2006	US20060257476 Tablet formulation
11/16/2006	US20060257475 Stable Sertraline Hydrochloride Formulation and Method
11/16/2006	US20060257474 anti-thrombocytic agent and an HMG-CoA reductase inhibitor in an amount sufficient to treat chronic glomerular nephritis wherein the anti-thrombocytic agent is selected from dilazep, dipyridamole and or salts thereof and the HMG-CoA reductase inhibitor is pitavastatin
11/16/2006	US20060257473 Extended release tablet
11/16/2006	US20060257472 Stability of progestogen formulations
11/16/2006	US20060257471 Pharmaceutical tablets of crystalline Type II aripiprazole
11/16/2006	US20060257470 Method for producing solid galenic formulations using a crosslinked non-thermoplastic carrier
11/16/2006	US20060257469 Enhanced indoleamine and catecholamine bio-availability via catechin inhibition of L-Dopa decarboxylase
11/16/2006	US20060257468 Dietary products comprising one or more of gamma-polyglutamic acid (gamma-PGA, H form) and gamma-polyglutamates for use as nutrition supplements
11/16/2006	US20060257467 Compositions and methods for inhibiting gastric acid secretion
11/16/2006	US20060257466 Administration of macrophage targeted formulations of compounds which modulate cholesterol-metabolizing enzymes for treatment of atherosclerosis
11/16/2006	US20060257465 Methods for preparation of lipid-encapsulated therapeutic agents
11/16/2006	US20060257464 Comprises cationic phospholipid derivatives which complex with DNA
11/16/2006	US20060257463 Transmucosal delivery of cannabinoids
11/16/2006	US20060257456 Material promoting wound healing
11/16/2006	US20060257454 Conjugated fatty acid esters
11/16/2006	US20060257435 Concentrated water-dispersible vitamin compositions
11/16/2006	US20060257434 Production of emulsions of pharmaceutical compositions
11/16/2006	US20060257433 Formulation
11/16/2006	US20060257432 Pharmaceutical formulations of xanthogenates and inhibitors of viral nucelic acid replication
11/16/2006	US20060257430 Methods of modulating intracellular degradation rates of toxins
11/16/2006	US20060257426 Emulsion comprising an aqueous phase, an oil phase, and a solvent and an immunogen
11/16/2006	US20060257392 Remedy or preventive for low turnover bone diseases
11/16/2006	US20060257385 Dietary supplement formulations for improved delivery of coenzyme Q10 and methods of administration
11/16/2006	US20060257379 Surgical system for the preparation of an implant and method for the preparation of an implant
11/16/2006	US20060257378 Adaptive SOL-GEL immobilization agents for cell delivery
11/16/2006	US20060257354 Ethylene copolymer waxes containing amino groups and use thereof
11/16/2006	US20060257334 Mssn dispersion and method for producing the same
11/16/2006	US20060257331 Oral Hygiene System and Method of Treatment
11/16/2006	US20060257330 Powdery pharmaceutical compositions for inhalation
11/16/2006	US20060257329 Delivery of drug esters through an inhalation route
11/16/2006	US20060257328 Delivery of caffeine through an inhalation route
11/16/2006	US20060257327 Medical product
11/16/2006	US20060257326 Methods and formulations for delivery of pharmacologically active agents
11/16/2006	US20060257323 Preventing insufflation and injection modes of drug abuse
11/16/2006	US20060255490 An extrudable insecticidally active formulation: phosphoroamido(di)thioate solids,a poly(alkylene oxide) polymeric lubricant, solid at ambient temperature and dissolved in a solvent, a dimethylsulfoxide or an alcohol, or alcohol-water azeotropic solvent
11/16/2006	US20060255323 Process for producing fine particles of organic compound
11/16/2006	US20060254903 Polygonal barrel spattering device, polygonal, barrel spattering method, coated particle formed by the device and method, microcapsule, and method of manufacturing the micro- capsule
11/16/2006	US20060254583 Dry powder inhaler system
11/16/2006	US20060254580 Digestible and volume adjustable multi medication delivery device
11/16/2006	DE59207523C5 Prepn. of compsn. contg. human protein and pharmaceuticals for infusion - contains preservatives which are opt. removed before storage, for germ free prod. giving minimal pain upon application
11/16/2006	DE202006010589U1 Composition, useful for reduction of penetration depth of body fluids into urethra, comprises two different hydrophobic compounds, where the hydrophobic compound is vegetable oil, and composition locks the urethra over the cross section
11/16/2006	DE102005038304A1 Verfahren zum Öffnen von Hohlstrukturen aus magnetischen Nanopartikeln A method for opening of hollow structures of magnetic nanoparticles
11/16/2006	CA2609296A1 Nanoparticulate and controlled release compositions comprising a cephalosporin
11/16/2006	CA2607912A1 Medical composition for promotion of skin regeneration
11/16/2006	CA2607802A1 Pharmaceutical formulation of apomorphine for buccal administration
11/16/2006	CA2607626A1 Modified release famciclovir pharmaceutical compositions
11/16/2006	CA2607624A1 Extrusion process for making compositions with poorly compressible therapeutic compounds
11/16/2006	CA2607608A1 Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
11/16/2006	CA2607500A1 Therapeutic foam
11/16/2006	CA2607427A1 Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
11/16/2006	CA2607336A1 Therapeutic sclerosing foam made preferably xenon

1 ... 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 ... 2991